期刊
HELIYON
卷 7, 期 4, 页码 -出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.heliyon.2021.e06558
关键词
Antidiabetic; Antineoplastic; Primary brain tumor; Metformin; Survival
资金
- PDUPT Grant, Ministry of Research and Higher Education, Republic of Indonesia, Indonesia [NKB-94/UN2.RST/HKP.05.00/2020]
Brain tumors are difficult to treat effectively, and current therapies are often inadequate. Metformin, a drug commonly used for type 2 diabetes, has shown potential benefits in improving the prognosis of brain tumor patients. Studies have indicated that combining metformin with chemotherapy can lead to better overall survival and progression-free survival, although further clinical testing is needed.
Brain tumors are challenging to handle and cause severe mortality and morbidity. The primary therapy for brain tumors, a combination of radiotherapy, chemotherapy (i.e temozolomide), and corticosteroids, is considered inadequate to improve patients' clinical conditions and associated with many adverse effects. There is an urgent need for new compounds or repurposing of existing therapies, which could improve brain tumor patients' prognosis. Metformin, commonly used for type 2 diabetes medication, has been examined for its protective action in cancer, reducing cancer risk and cancer-related mortality. However, its effect on cancer is still in rigorous debate. This study examines recent studies on the effects of metformin in primary brain tumor patients through systematic reviews. The literature search was performed on PubMed, ScienceDirect, and SpringerLink databases for articles published between 2013 and 2020. We selected clinical studies comparing the therapeutic outcomes of brain tumor therapy with and without metformin. The clinical benefits of the drug were assessed through the overall survival (OS) and progression-free survival (PFS) of brain tumor patients. Those studies demonstrated that the combination of metformin with temozolomide given post-radiotherapy resulted in better OS and PFS. Nonetheless, the efficacy and safety of metformin need further clinical testing in the wider population.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据